Drug Topics
MARCH 24, 2025
Emily Leppien, PharmD, BCPS, BCPP, clinical associate professor of pharmacy practice at Binghamton University, discusses identifying potential red flags for substance use disorder.
The FDA Law Blog
FEBRUARY 11, 2025
Houck One of the most significant issues facing hospitals and other facilities is the diversion of controlled substances meant for patients by physicians, pharmacists, nurses and other trusted healthcare employees.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmExec
DECEMBER 20, 2024
In this part of his Pharmaceutical Executive video interview, Peter Ax, CEO of UpScriptHealth, discusses the recent DEA extensions of telehealth for controlled substances and new treatment modalities or patient populations he anticipates will become more accessible through telehealth in 2025.
The FDA Law Blog
DECEMBER 12, 2024
The NPRM seeks to reschedule marijuana from schedule I of the federal Controlled Substances Act (CSA) to schedule III. Last weeks prehearing conference set the parameters for the hearing on the merits, scheduled to begin January 21, 2025. Prehearing Ruling (Dec. 4, 2024), at 1.
pharmaphorum
DECEMBER 14, 2022
Harmony Biosciences introduced Wakix to the market in 2019 as the first non-controlled substance for the treatment of narcolepsy. For Avadel’s Lumryz, the one-dose extended-release oral suspension that allows narcolepsy patients to sleep through the night, the worst-case scenario is it won’t be on the market until 2025.
OctariusRx
FEBRUARY 24, 2025
The 2025 controlled substance assessment quiz is about to be released! This is our annual competency assessment focused on controlled substances and regulatory compliance. The quiz focuses on some of the basic elements managing controlled substances. How are you assessing your staff?
The FDA Law Blog
FEBRUARY 18, 2025
23, 2025), DEA reviewed evidence from an administrative hearing and upheld the Administrative Law Judges (ALJs) recommended decision to revoke the registration of a pharmacy that DEA alleged dispensed controlled substances to patients without resolving numerous red flags of diversion. In Neumanns Pharmacy, LLC , 90 Fed.
Expert insights. Personalized for you.
281 
Let's personalize your content